FDA expanded the approval of Shingrix, an adjuvanted recombinant zoster vaccine, for adults at increased risk of shingles due to immunosuppression, manufacturer GlaxoSmithKline (GSK) announced on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback